300233 金城医药
已收盘 04-15 15:00:00
资讯
新帖
简况
金城医药最新公告：子公司收到注射用乳糖酸红霉素药品注册证书
证券之星 · 04-10
金城医药最新公告：子公司收到注射用乳糖酸红霉素药品注册证书
股市必读：金城医药（300233）预计2026年1-3月扣非后净利润盈利4900万元至5900万元
证券之星 · 04-09
股市必读：金城医药（300233）预计2026年1-3月扣非后净利润盈利4900万元至5900万元
金城医药最新公告：预计一季度归母净利润同比增长51.19%—85.42%
证券之星 · 04-08
金城医药最新公告：预计一季度归母净利润同比增长51.19%—85.42%
金城医药：截至2026年3月31日，公司股东总户数为28,811户
证券之星 · 04-03
金城医药：截至2026年3月31日，公司股东总户数为28,811户
金城医药（300233）披露董事会专门委员会关于2025年度及换届相关事项的专门意见，3月30日股价下跌1.83%
证券之星 · 03-30
金城医药（300233）披露董事会专门委员会关于2025年度及换届相关事项的专门意见，3月30日股价下跌1.83%
金城医药（300233）披露2025年年度报告，3月27日股价上涨2.53%
中金财经 · 03-27
金城医药（300233）披露2025年年度报告，3月27日股价上涨2.53%
金城医药(300233.SZ)发布2025年度业绩，归母净利润4418.63万元，下降77.55%
智通财经 · 03-26
金城医药(300233.SZ)发布2025年度业绩，归母净利润4418.63万元，下降77.55%
金城医药(300233)3月10日股东户数2.92万户，较上期减少0.2%
中金财经 · 03-16
金城医药(300233)3月10日股东户数2.92万户，较上期减少0.2%
3月3日金城医药跌6.39%，大成卓享一年持有混合A基金重仓该股
证券之星 · 03-03
3月3日金城医药跌6.39%，大成卓享一年持有混合A基金重仓该股
金城医药最新公告：子公司金城泰尔和金城素智分别收到比索洛尔氨氯地平片和头孢地尼干混悬剂的药品注册证书
证券之星 · 02-25
金城医药最新公告：子公司金城泰尔和金城素智分别收到比索洛尔氨氯地平片和头孢地尼干混悬剂的药品注册证书
股市必读：金城医药(300233)股东户数2.92万户，较上期增加0.31%
证券之星 · 02-12
股市必读：金城医药(300233)股东户数2.92万户，较上期增加0.31%
金城医药最新公告：子公司拟中选国家组织集采药品协议期满品种接续采购
证券之星 · 02-11
金城医药最新公告：子公司拟中选国家组织集采药品协议期满品种接续采购
股市必读：金城医药（300233）预计2025年全年归属净利润盈利4000万元至5300万元
证券之星 · 02-02
股市必读：金城医药（300233）预计2025年全年归属净利润盈利4000万元至5300万元
金城医药：预计2025年全年扣非后净利润盈利2800万元至3700万元
证券之星 · 01-30
金城医药：预计2025年全年扣非后净利润盈利2800万元至3700万元
金城医药（300233）披露签署权益许可和经销协议之补充协议，1月26日股价上涨2.91%
证券之星 · 01-26
金城医药（300233）披露签署权益许可和经销协议之补充协议，1月26日股价上涨2.91%
金城医药与Theramex深化合作，再获五款女性健康产品中国独家权益
中金财经 · 01-26
金城医药与Theramex深化合作，再获五款女性健康产品中国独家权益
金城医药最新公告：子公司金城金素收到注射用头孢呋辛钠药品补充申请批准通知书
中金财经 · 01-21
金城医药最新公告：子公司金城金素收到注射用头孢呋辛钠药品补充申请批准通知书
金城医药：截至2026年1月20日股东总户数为29,110户
证券之星 · 01-21
金城医药：截至2026年1月20日股东总户数为29,110户
金城医药控股股东金城实业质押展期，涉及178.64万股
中金财经 · 01-12
金城医药控股股东金城实业质押展期，涉及178.64万股
股市必读：金城医药（300233）1月8日董秘有最新回复
证券之星 · 01-09
股市必读：金城医药（300233）1月8日董秘有最新回复
加载更多
公司概况
公司名称：
山东金城医药集团股份有限公司
所属行业：
医药制造业
上市日期：
2011-06-22
主营业务：
山东金城医药集团股份有限公司的主营业务是医药中间体、原料药、口服及外用制剂以及注射剂的研发、生产和销售。公司的主要产品是硝呋太尔制霉素阴道软胶囊、硝呋太尔胶囊、普罗雌烯乳膏、普罗雌烯氯喹那多阴道片以及注射用头孢唑林钠、注射用头孢他啶、注射用头孢呋辛钠、头孢羟氨苄胶囊、头孢克洛分散片、烟碱、4-AA、4-BMA、EDC、DIC。金城医化、金城汇海通过工信部“绿色工厂”复审，金城医化、金城生物、金城柯瑞通过重点行业绩效分级B级复审。
发行价格：
18.60
{"stockData":{"symbol":"300233","market":"SZ","secType":"STK","nameCN":"金城医药","latestPrice":15.6,"timestamp":1776236586000,"preClose":15.8,"halted":0,"volume":14196890,"delay":0,"changeRate":-0.0127,"floatShares":370000000,"shares":384000000,"eps":-0.2825,"marketStatus":"已收盘","change":-0.2,"latestTime":"04-15 15:00:00","open":15.9,"high":15.9,"low":15.5,"amount":222000000,"amplitude":0.0253,"askPrice":15.61,"askSize":189,"bidPrice":15.6,"bidSize":278,"shortable":0,"etf":0,"ttmEps":-0.2825,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776303000000},"marketStatusCode":5,"adr":0,"adjPreClose":15.8,"symbolType":"stock","openAndCloseTimeList":[[1776216600000,1776223800000],[1776229200000,1776236400000]],"highLimit":17.38,"lowLimit":14.22,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":383874587,"isCdr":false,"pbRate":1.66,"roa":"--","roe":"1.19%","epsLYR":0.12,"committee":0.145783,"marketValue":5988000000,"turnoverRate":0.0384,"status":1,"floatMarketCap":5769000000},"requestUrl":"/m/hq/s/300233","defaultTab":"news","newsList":[{"id":"2626935761","title":"金城医药最新公告：子公司收到注射用乳糖酸红霉素药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2626935761","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626935761?lang=zh_cn&edition=full","pubTime":"2026-04-10 17:03","pubTimestamp":1775811791,"startTime":"0","endTime":"0","summary":"金城医药公告称，公司控股子公司广东金城金素制药有限公司于近日收到国家药监局下发的注射用乳糖酸红霉素《药品注册证书》，涉及0.25g和0.5g两种规格。此前，公司子公司北京金城泰尔制药有限公司已于2025年获得该原料药上市许可。本次获证实现了公司原料制剂一体化布局，丰富了抗生素类产品管线，有利于提升市场竞争力。鉴于药品销售受政策及市场环境等因素影响，存在不确定性，敬请投资者注意风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041000028500.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626926455","title":"股市必读：金城医药（300233）预计2026年1-3月扣非后净利润盈利4900万元至5900万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2626926455","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626926455?lang=zh_cn&edition=full","pubTime":"2026-04-09 01:18","pubTimestamp":1775668693,"startTime":"0","endTime":"0","summary":"截至2026年4月8日收盘，金城医药报收于14.8元，上涨2.07%，换手率2.13%，成交量7.89万手，成交额1.16亿元。交易信息汇总资金流向4月8日主力资金净流入650.29万元；游资资金净流入475.52万元；散户资金净流出1125.8万元。金城医药发布业绩预告，预计2026年1-3月归属净利润盈利5300万元至6500万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040900001068.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625912788","title":"金城医药最新公告：预计一季度归母净利润同比增长51.19%—85.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625912788","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625912788?lang=zh_cn&edition=full","pubTime":"2026-04-08 17:47","pubTimestamp":1775641628,"startTime":"0","endTime":"0","summary":"金城医药(300233.SZ)披露业绩预告，预计一季度归母净利润5300万元—6500万元，同比增长51.19%—85.42%。报告期内，公司中间体板块部分产品销量较去年同期增加，产能利用率提高。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040800027805.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624658522","title":"金城医药：截至2026年3月31日，公司股东总户数为28,811户","url":"https://stock-news.laohu8.com/highlight/detail?id=2624658522","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624658522?lang=zh_cn&edition=full","pubTime":"2026-04-03 15:00","pubTimestamp":1775199643,"startTime":"0","endTime":"0","summary":"证券之星消息，金城医药(300233)04月02日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截至2026年3月 31日公司的股东总数是多少？谢谢金城医药回复：投资者，您好，截至2026年3月31日，公司股东总户数为28,811户。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300023597.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300233","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623241313","title":"金城医药（300233）披露董事会专门委员会关于2025年度及换届相关事项的专门意见，3月30日股价下跌1.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623241313","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623241313?lang=zh_cn&edition=full","pubTime":"2026-03-30 17:34","pubTimestamp":1774863263,"startTime":"0","endTime":"0","summary":"截至2026年3月30日收盘，金城医药报收于13.94元，较前一交易日下跌1.83%，最新总市值为53.51亿元。近日，金城医药发布《山东金城医药集团股份有限公司董事会专门委员会关于2025年度及第六届董事会第二十一次会议相关事项的专门意见》公告。公告显示，公司董事会各专门委员会就2025年度报告、续聘2026年度会计师事务所、2025年度内部控制自我评价报告、董事会换届选举及董事候选人任职资格、董事及高管薪酬等事项发表专门意见。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000024180.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622878015","title":"金城医药（300233）披露2025年年度报告，3月27日股价上涨2.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622878015","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622878015?lang=zh_cn&edition=full","pubTime":"2026-03-27 22:43","pubTimestamp":1774622603,"startTime":"0","endTime":"0","summary":"h2,h3,h4{padding: 10px 0;font-size: 16px;line-height: 30px;color:#262626;font-weight: 600;}h2{border-bottom: 1px solid #d8dee4; padding-bottom: 0.3em}.article_content ul{padding-left:22px;}截至2026年3月27日收盘，金城医药报收于14.2元，较前一交易日上涨2.53%，最新总市值为54.51亿元。金城医药于2026年3月27日披露《2025年年度报告》。报告显示，截至2025年末，公司总资产为5,190,891,672.08元，较上年末减少7.39%；归属于上市公司股东的净资产为3,663,385,616.50元，同比下降2.75%。2025年营业收入为2,736,927,222.73元，同比下滑18.87%；归属于上市公司股东的净利润为44,186,259.69元，同比下降77.55%；扣除非经常性损益后的净利润为30,163,155.91元，同比下降83.23%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260327/32105345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0028","300233","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622865986","title":"金城医药(300233.SZ)发布2025年度业绩，归母净利润4418.63万元，下降77.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622865986","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622865986?lang=zh_cn&edition=full","pubTime":"2026-03-26 21:46","pubTimestamp":1774532794,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金城医药(300233.SZ)发布2025年年度报告，该公司营业收入为27.37亿元，同比减少18.87%。归属于上市公司股东的净利润为4418.63万元，同比减少77.55%。归属于上市公司股东的扣除非经常性损益的净利润为3016.32万元，同比减少83.23%。基本每股收益为0.12元。此外，拟向全体股东每10股派发现金红利1.5元(含税)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419889.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"金城医药(300233.SZ)发布2025年度业绩，归母净利润4418.63万元，下降77.55%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619562504","title":"金城医药(300233)3月10日股东户数2.92万户，较上期减少0.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619562504","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619562504?lang=zh_cn&edition=full","pubTime":"2026-03-16 17:21","pubTimestamp":1773652882,"startTime":"0","endTime":"0","summary":"证券之星消息，近日金城医药披露，截至2026年3月10日公司股东户数为2.92万户，较2月10日减少58.0户，减幅为0.2%。在化学制药行业个股中，金城医药股东户数低于行业平均水平，截至3月10日，化学制药行业平均股东户数为3.42万户。从股价来看，2026年2月10日至2026年3月10日，金城医药区间跌幅为1.94%，在此期间股东户数减少58.0户，减幅为0.2%。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202603/16/20260316972751.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202603/16/20260316972751.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260316/32071647.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300233","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616172103","title":"3月3日金城医药跌6.39%，大成卓享一年持有混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2616172103","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616172103?lang=zh_cn&edition=full","pubTime":"2026-03-03 16:52","pubTimestamp":1772527970,"startTime":"0","endTime":"0","summary":"证券之星消息，3月3日金城医药跌6.39%，收盘报14.66元，换手率3.48%，成交量12.94万手，成交额1.95亿元。重仓金城医药的公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为大成基金的大成卓享一年持有混合A。大成卓享一年持有混合A目前规模为1.46亿元，最新净值1.1819，较上一交易日下跌0.48%，近一年上涨11.62%。该公募基金现任基金经理为苏秉毅。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030300029491.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614701865","title":"金城医药最新公告：子公司金城泰尔和金城素智分别收到比索洛尔氨氯地平片和头孢地尼干混悬剂的药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2614701865","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614701865?lang=zh_cn&edition=full","pubTime":"2026-02-25 16:31","pubTimestamp":1772008264,"startTime":"0","endTime":"0","summary":"金城医药(300233.SZ)公告称，公司全资子公司金城泰尔和金城素智分别收到国家药品监督管理局下发的比索洛尔氨氯地平片和头孢地尼干混悬剂的《药品注册证书》。比索洛尔氨氯地平片为高血压治疗的替代疗法，头孢地尼干混悬剂为口服抗感染药物。这两个产品的获批将进一步丰富公司产品线，并为后续其他产品研发积累经验。然而，药品销售受市场环境等不确定因素影响，投资者需注意风险。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500025724.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300233","EWW","MXPmain","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610995761","title":"股市必读：金城医药(300233)股东户数2.92万户，较上期增加0.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610995761","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610995761?lang=zh_cn&edition=full","pubTime":"2026-02-12 00:50","pubTimestamp":1770828622,"startTime":"0","endTime":"0","summary":"截至2026年2月11日收盘，金城医药报收于15.53元，上涨0.32%，换手率1.19%，成交量4.42万手，成交额6878.38万元。当日关注点来自交易信息汇总：2月11日主力资金净流入282.2万元，散户资金呈净流出态势。来自股本股东变化：截至2026年1月30日，公司股东户数较前期小幅上升0.31%，户均持股数量下降至1.31万股。股本股东变化股东户数变动近日金城医药披露，截至2026年1月30日公司股东户数为2.92万户，较1月20日增加89.0户，增幅为0.31%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021200001111.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300233","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610593964","title":"金城医药最新公告：子公司拟中选国家组织集采药品协议期满品种接续采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2610593964","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610593964?lang=zh_cn&edition=full","pubTime":"2026-02-11 19:19","pubTimestamp":1770808782,"startTime":"0","endTime":"0","summary":"金城医药(300233.SZ)公告称，公司控股子公司金城金素及全资子公司金城素智参加了国家组织集采药品协议期满品种接续采购，头孢唑林钠注射剂、头孢曲松钠注射剂等七个品种拟中选。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021100032847.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608885105","title":"股市必读：金城医药（300233）预计2025年全年归属净利润盈利4000万元至5300万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608885105","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608885105?lang=zh_cn&edition=full","pubTime":"2026-02-02 01:32","pubTimestamp":1769967131,"startTime":"0","endTime":"0","summary":"业绩披露要点金城医药发布业绩预告，预计2025年全年归属净利润盈利4000万元至5300万元。公司公告汇总山东金城医药集团股份有限公司发布2025年度业绩预告，预计归属于上市公司股东的净利润为4,000万元至5,300万元，比上年同期下降79.67%至73.07%；扣除非经常性损益后的净利润为2,800万元至3,700万元，同比下降84.44%至79.43%。非经常性损益对净利润影响为1,200万元至1,600万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200000721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607019895","title":"金城医药：预计2025年全年扣非后净利润盈利2800万元至3700万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607019895","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607019895?lang=zh_cn&edition=full","pubTime":"2026-01-30 18:18","pubTimestamp":1769768335,"startTime":"0","endTime":"0","summary":"证券之星消息，金城医药发布业绩预告，预计2025年全年扣非后净利润盈利2800万元至3700万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000034187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606246712","title":"金城医药（300233）披露签署权益许可和经销协议之补充协议，1月26日股价上涨2.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606246712","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606246712?lang=zh_cn&edition=full","pubTime":"2026-01-26 22:24","pubTimestamp":1769437483,"startTime":"0","endTime":"0","summary":"截至2026年1月26日收盘，金城医药报收于16.25元，较前一交易日上涨2.91%，最新总市值为62.38亿元。金城医药于2026年1月26日发布《关于签署权益许可和经销协议之补充协议的公告》。公告显示，山东金城医药集团股份有限公司与Theramex签署《权益许可和经销协议之补充协议1》，获得利塞膦酸钠片、利塞膦酸钠肠溶片、雌二醇贴片等产品在中国境内的独家排他商业化权益。金城医药负责注册、分销、市场推广及监管事务，Theramex作为上市许可持有人供货。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600035819.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606213146","title":"金城医药与Theramex深化合作，再获五款女性健康产品中国独家权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2606213146","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606213146?lang=zh_cn&edition=full","pubTime":"2026-01-26 17:00","pubTimestamp":1769418021,"startTime":"0","endTime":"0","summary":"中访网数据 山东金城医药集团股份有限公司今日公告，公司与英国女性健康药物公司Theramex HQ UK Limited签署了《权益许可和经销协议之补充协议1》，进一步深化双方在女性健康领域的战略合作。Theramex将继续作为产品在上述区域的上市许可持有人，金城医药则作为指定代理人，负责合作产品的注册、分销、市场推广及相关监管事务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260126/31972576.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300233","BK0028","BK0239","FHCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605108273","title":"金城医药最新公告：子公司金城金素收到注射用头孢呋辛钠药品补充申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2605108273","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605108273?lang=zh_cn&edition=full","pubTime":"2026-01-21 18:14","pubTimestamp":1768990453,"startTime":"0","endTime":"0","summary":"金城医药(300233.SZ)公告称，公司控股子公司广东金城金素制药有限公司收到国家药品监督管理局下发的注射用头孢呋辛钠《药品补充申请批准通知书》。该药品为公司原研药地产化产品，适用于多种细菌引起的感染，并可用于外科手术中的感染预防。此次质量标准的修订对产品质量提升有积极意义，但药品销售受政策和市场环境影响，投资者需注意相关风险。为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260121/31960680.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0028","300233","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605724521","title":"金城医药：截至2026年1月20日股东总户数为29,110户","url":"https://stock-news.laohu8.com/highlight/detail?id=2605724521","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605724521?lang=zh_cn&edition=full","pubTime":"2026-01-21 16:57","pubTimestamp":1768985863,"startTime":"0","endTime":"0","summary":"证券之星消息，金城医药(300233)01月21日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司截止到一月二十日股东人数是多少？金城医药回复：投资者，您好，截至2026年1月20日，公司股东总户数为29,110户。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100027415.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602518870","title":"金城医药控股股东金城实业质押展期，涉及178.64万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2602518870","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602518870?lang=zh_cn&edition=full","pubTime":"2026-01-12 17:23","pubTimestamp":1768209791,"startTime":"0","endTime":"0","summary":"中访网数据 山东金城医药集团股份有限公司于2026年1月12日发布公告，其控股股东淄博金城实业投资股份有限公司对其持有的部分公司股份办理了质押展期。本次展期涉及股份数量为1,786,400股，占公司总股本的0.47%，占金城实业所持股份的2.27%。公司强调，本次操作仅为质押展期，不涉及新增融资。截至公告日，金城实业及其一致行动人合计持有公司24.08%的股份，其中处于质押状态的股份为17,588,900股，占其合计持股的19.02%，占公司总股本的4.58%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260112/31934721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0028","300233","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602391845","title":"股市必读：金城医药（300233）1月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2602391845","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602391845?lang=zh_cn&edition=full","pubTime":"2026-01-09 01:04","pubTimestamp":1767891853,"startTime":"0","endTime":"0","summary":"截至2026年1月8日收盘，金城医药报收于14.79元，上涨2.71%，换手率3.25%，成交量12.1万手，成交额1.78亿元。董秘最新回复投资者： 1，2025年核定的烟碱生产量为200吨是否能满足公司的国内外客户需求量？后续公司也将结合行业政策、市场变化及自身战略发展规划，加强产品创新及市场布局，不断提高市场竞争力。当日关注点来自交易信息汇总：1月8日主力资金净流入2406.34万元，显示主力对金城医药股票的积极介入。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900000779.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300233"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1776244133125,"stockEarnings":[{"period":"1week","weight":0.0897},{"period":"1month","weight":0.0381},{"period":"3month","weight":0.0083},{"period":"6month","weight":-0.0846},{"period":"1year","weight":-0.0262},{"period":"ytd","weight":0.1294}],"compareEarnings":[{"period":"1week","weight":0.0351},{"period":"1month","weight":-0.0168},{"period":"3month","weight":-0.0241},{"period":"6month","weight":0.0282},{"period":"1year","weight":0.2341},{"period":"ytd","weight":0.0146}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"山东金城医药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"28811人(较上一季度减少1.34%)","perCapita":"12835股","listingDate":"2011-06-22","address":"山东省淄博市淄川区经济开发区双山路1号","registeredCapital":"38387万元","survey":" 山东金城医药集团股份有限公司的主营业务是医药中间体、原料药、口服及外用制剂以及注射剂的研发、生产和销售。公司的主要产品是硝呋太尔制霉素阴道软胶囊、硝呋太尔胶囊、普罗雌烯乳膏、普罗雌烯氯喹那多阴道片以及注射用头孢唑林钠、注射用头孢他啶、注射用头孢呋辛钠、头孢羟氨苄胶囊、头孢克洛分散片、烟碱、4-AA、4-BMA、EDC、DIC。金城医化、金城汇海通过工信部“绿色工厂”复审，金城医化、金城生物、金城柯瑞通过重点行业绩效分级B级复审。","listedPrice":18.6},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.41.0","shortVersion":"4.41.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"金城医药(300233)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供金城医药(300233)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"金城医药,300233,金城医药股票,金城医药股票老虎,金城医药股票老虎国际,金城医药行情,金城医药股票行情,金城医药股价,金城医药股市,金城医药股票价格,金城医药股票交易,金城医药股票购买,金城医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"金城医药(300233)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供金城医药(300233)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}